<DOC>
	<DOCNO>NCT00992251</DOCNO>
	<brief_summary>The objective registry collect data patient demographic , medical history , change prostate , bone overall health patient receive androgen ablation treatment use Eligard . Data collect national registry program provide opportunity increase knowledge efficacy safety long term treatment Eligard , provide platform good identify patient segment therapy Eligard® . Furthermore registries tool accurately capture rare adverse event .</brief_summary>
	<brief_title>Eligard Observational Registry Patients With Prostate Cancer</brief_title>
	<detailed_description>354 patient enrol study . Only 88 patient complete study . For patient complete three year data collection , 10 % consider Castrate Resistant remain Eligard® . For patient complete 3 year follow-up , 8.8 % consider Castrate Resistant continue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients &gt; 18 year age . Histologically confirm diagnosis locally Advanced Metastatic Prostate Cancer . Patient start androgen deprivation therapy Eligard 3 4 month treatment frequency per standard care . Signed write informed consent . Prior ADT ( within 6 month ) . Any concurrent condition would make undesirable , physician 's opinion , subject participate study would jeopardize compliance protocol . Life expectancy le 2 year .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>